Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free HIMS Stock Alerts

Hims & Hers Health (HIMS) Competitors

Hims & Hers Health logo
$34.45 -1.00 (-2.82%)
Closing price 07/10/2026 03:59 PM Eastern
Extended Trading
$34.23 -0.22 (-0.65%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HIMS vs. GH, BTSG, FMS, PACS, and BLLN

Should you buy Hims & Hers Health stock or one of its competitors? MarketBeat compares Hims & Hers Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hims & Hers Health include Guardant Health (GH), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), PACS Group (PACS), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Hims & Hers Health compare to Guardant Health?

Guardant Health (NASDAQ:GH) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Guardant Health has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Guardant Health currently has a consensus target price of $155.70, suggesting a potential downside of 2.72%. Hims & Hers Health has a consensus target price of $30.70, suggesting a potential downside of 10.88%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Guardant Health is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health
1 Sell rating(s)
0 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.96
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

Hims & Hers Health has a net margin of -0.56% compared to Guardant Health's net margin of -40.10%. Hims & Hers Health's return on equity of 6.10% beat Guardant Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Guardant Health-40.10% N/A -26.42%
Hims & Hers Health -0.56%6.10%1.52%

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Hims & Hers Health had 2 more articles in the media than Guardant Health. MarketBeat recorded 10 mentions for Hims & Hers Health and 8 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.99 beat Hims & Hers Health's score of 0.83 indicating that Guardant Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardant Health
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hims & Hers Health has higher revenue and earnings than Guardant Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$982.02M21.61-$416.28M-$3.39N/A
Hims & Hers Health$2.35B3.40$128.37M-$0.09N/A

Summary

Hims & Hers Health beats Guardant Health on 9 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, BrightSpring Health Services had 1 more articles in the media than Hims & Hers Health. MarketBeat recorded 11 mentions for BrightSpring Health Services and 10 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.83 beat BrightSpring Health Services' score of 0.28 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BrightSpring Health Services
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hims & Hers Health
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BrightSpring Health Services has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

BrightSpring Health Services currently has a consensus price target of $66.56, indicating a potential downside of 6.81%. Hims & Hers Health has a consensus price target of $30.70, indicating a potential downside of 10.88%. Given BrightSpring Health Services' stronger consensus rating and higher possible upside, equities research analysts clearly believe BrightSpring Health Services is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
3.00
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

BrightSpring Health Services has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$12.91B1.09$190.67M$1.4150.66
Hims & Hers Health$2.35B3.40$128.37M-$0.09N/A

63.5% of Hims & Hers Health shares are owned by institutional investors. 2.8% of BrightSpring Health Services shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BrightSpring Health Services has a net margin of 2.27% compared to Hims & Hers Health's net margin of -0.56%. BrightSpring Health Services' return on equity of 14.63% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health Services2.27% 14.63% 4.41%
Hims & Hers Health -0.56%6.10%1.52%

Summary

BrightSpring Health Services beats Hims & Hers Health on 12 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$22.20B0.58$1.11B$1.9012.65
Hims & Hers Health$2.35B3.40$128.37M-$0.09N/A

Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Hims & Hers Health's net margin of -0.56%. Fresenius Medical Care AG & Co. KGaA's return on equity of 8.90% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Fresenius Medical Care AG & Co. KGaA4.88% 8.90% 4.05%
Hims & Hers Health -0.56%6.10%1.52%

In the previous week, Hims & Hers Health had 7 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 10 mentions for Hims & Hers Health and 3 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.65 beat Hims & Hers Health's score of 0.83 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fresenius Medical Care AG & Co. KGaA
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Hims & Hers Health
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fresenius Medical Care AG & Co. KGaA currently has a consensus price target of $28.00, suggesting a potential upside of 16.52%. Hims & Hers Health has a consensus price target of $30.70, suggesting a potential downside of 10.88%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, equities research analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fresenius Medical Care AG & Co. KGaA
4 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.56
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

Fresenius Medical Care AG & Co. KGaA beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

How does Hims & Hers Health compare to PACS Group?

PACS Group (NYSE:PACS) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

PACS Group has a net margin of 4.49% compared to Hims & Hers Health's net margin of -0.56%. PACS Group's return on equity of 26.47% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
PACS Group4.49% 26.47% 4.36%
Hims & Hers Health -0.56%6.10%1.52%

63.5% of Hims & Hers Health shares are held by institutional investors. 70.1% of PACS Group shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PACS Group has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

In the previous week, PACS Group had 13 more articles in the media than Hims & Hers Health. MarketBeat recorded 23 mentions for PACS Group and 10 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.83 beat PACS Group's score of 0.01 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PACS Group
7 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hims & Hers Health
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PACS Group has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PACS Group$5.29B1.29$191.54M$1.5627.72
Hims & Hers Health$2.35B3.40$128.37M-$0.09N/A

PACS Group presently has a consensus target price of $50.60, suggesting a potential upside of 17.02%. Hims & Hers Health has a consensus target price of $30.70, suggesting a potential downside of 10.88%. Given PACS Group's stronger consensus rating and higher probable upside, research analysts clearly believe PACS Group is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

PACS Group beats Hims & Hers Health on 12 of the 16 factors compared between the two stocks.

How does Hims & Hers Health compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Billiontoone presently has a consensus price target of $126.00, suggesting a potential downside of 0.61%. Hims & Hers Health has a consensus price target of $30.70, suggesting a potential downside of 10.88%. Given Billiontoone's stronger consensus rating and higher probable upside, research analysts plainly believe Billiontoone is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Billiontoone has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Billiontoone's return on equity.

Company Net Margins Return on Equity Return on Assets
BilliontooneN/A N/A N/A
Hims & Hers Health -0.56%6.10%1.52%

In the previous week, Hims & Hers Health had 3 more articles in the media than Billiontoone. MarketBeat recorded 10 mentions for Hims & Hers Health and 7 mentions for Billiontoone. Hims & Hers Health's average media sentiment score of 0.83 beat Billiontoone's score of -0.05 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Billiontoone
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hims & Hers Health
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hims & Hers Health has higher revenue and earnings than Billiontoone. Hims & Hers Health is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Billiontoone$305.11M19.11$7.45M$0.55230.49
Hims & Hers Health$2.35B3.40$128.37M-$0.09N/A

Summary

Hims & Hers Health beats Billiontoone on 8 of the 15 factors compared between the two stocks.

Get Hims & Hers Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIMS vs. The Competition

Export
MetricHims & Hers HealthMEDICAL INFO SYS IndustryMedical SectorNYSE Exchange
Market Cap$8.21B$1.84B$7.14B$23.42B
Dividend YieldN/AN/A2.68%4.04%
P/E Ratio-382.7776.5127.4231.40
Price / Sales3.407.39593.1920.39
Price / Cash42.3627.8249.3425.05
Price / Book14.475.6310.884.77
Net Income$128.37M-$54.76M$3.59B$1.07B
7 Day Performance-6.26%1.37%-0.26%-0.50%
1 Month Performance19.77%5.49%4.52%0.64%
1 Year Performance-28.10%-1.21%29.17%16.94%

Hims & Hers Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIMS
Hims & Hers Health
2.838 of 5 stars		$34.45
-2.8%		$30.70
-10.9%		-31.4%$8.21B$2.35BN/A2,442
GH
Guardant Health
2.568 of 5 stars		$163.65
+9.1%		$144.82
-11.5%		+212.0%$21.66B$982.02MN/A2,506
BTSG
BrightSpring Health Services
2.7077 of 5 stars		$68.88
-1.2%		$61.27
-11.0%		+242.4%$13.60B$12.91B48.8823,500
FMS
Fresenius Medical Care AG & Co. KGaA
4.373 of 5 stars		$22.88
+1.2%		$28.00
+22.4%		-12.3%$12.36B$22.20B12.041,488
PACS
PACS Group
3.2973 of 5 stars		$44.49
+4.3%		$48.00
+7.9%		+238.1%$6.98B$5.29B28.2947,455

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:HIMS) was last updated on 7/11/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel